Paul Scotti (@pscotti)
Activity by Paul Scotti
CHICAGO — Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.
Joe Dangor (on-site at ASCO), Mayo Clinic Public Affairs, 651-261-9089 (cell), email@example.com.
Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199 (office), firstname.lastname@example.org.
JACKSONVILLE, Fla. — Mayo Clinic’s Florida campus has been recognized by the American Nurses Credentialing Center (ANCC) with a Magnet Recognition Program® designation. This credential recognizes health care organizations for quality patient care, nursing excellence and innovations in professional nursing practice. Mayo Clinic is one of only 20 hospitals in Florida and 401 nationally with Magnet Recognition Program status.
In the nursing profession, Magnet recognition is considered the gold seal that epitomizes the importance of quality, safety and improvement; intradisciplinary and interdisciplinary teamwork; understanding of evidence based practice and research; and formal nursing education. It requires organizations to develop, disseminate and enculturate evidenced-based criteria that results in a positive work environment for nurses and, by extension, all employees. U.S. News & World Report includes the Magnet designation as a primary competence indicator in its assessment of almost 5,000 hospitals to rank and report the best medical centers in 16 specialties.
JACKSONVILLE, Fla. — Patients with liver cancer can be cured with a liver transplant. But because of the shortage of donated organs, these patients often die waiting for a liver. That’s because most transplant centers predominantly use livers from donors who die from brain death.
But in the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have the same beneficial outcomes using organs donated by patients who died of cardiac death. The study was recently published online in the American Journal of Transplantation.
MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199, email@example.com
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when trastuzumab is used.
JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.
Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment.
“This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida.
Journalists: Soundbites with Dr. Pungpapong are available in the downloads.
Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit
JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.
These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. [...]
JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo. [...]
JACKSONVILLE, Florida, 30 de septiembre 2014 — Investigaciones en más de 8.000 mujeres, que participaron en el estudio más grande del mundo de dos tratamientos para el cáncer de mama HER2-positivo, refuerzan otros hallazgos de este ensayo clínico que demuestran que el fármaco trastuzumab (Herceptin) debiera seguir siendo el tratamiento estándar en este tipo de cáncer, expresa una investigadora de la Clínica Mayo. [...]